QRxPharma

QRxPharma is an Australian specialty pharmaceutical company focused on developing and commercializing innovative pain management and abuse prevention products. The company's portfolio includes both late and early-stage clinical drug candidates, designed to offer reduced risk, shorter development timelines, and improved patient outcomes. In Q4 2013, QRxPharma plans to resubmit a New Drug Application with the US Food and Drug Administration for its main product, immediate release MOXDUO®, aimed at treating acute pain. The company has secured strategic partnerships with Actavis Inc., Paladin Labs Inc., and Aspen Group for the commercialization of immediate release MOXDUO in the United States, Canada, Australia, and South Africa. Additionally, QRxPharma is working on intravenous (IV) and controlled-release (CR) formulations of MOXDUO, as well as with Aesica Formulation Development Limited to promote its proprietary Stealth Beadlets™ abuse deterrent technology on a global scale. The company received a $11.60M investment in post-IPO equity at 13 December 2013. Overall, QRxPharma is pioneering pain management and abuse prevention in the biopharma, biotechnology, and healthcare industries.